Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perindopril for Regorafenib-induced HFSR in mCRC
NCT02651415Phase 2Completed
- Sponsor
- BC Cancer
- Start
- Aug 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of perindopril in Hand-foot skin reaction (HFSR) and hypertension (HTN), sponsored by BC Cancer. Primary endpoint: Number of Participants That Have Any Grade HFSR Toxicity. Started Aug 2016; status: completed.
02
Drugs
perindopril
03
Conditions
Hand-foot skin reaction (HFSR)hypertension (HTN)
Beyond the preview
Go deeper on NCT02651415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02651415.